A PYMNTS Company

US: AbbVie hit with antitrust lawsuit over Humira “patent thicket”

 |  March 20, 2019

AbbVie used a dense web of 100-plus patents to insulate its blockbuster drug Humira from US competition while cutting deals with rivals that delayed the release of cheaper biosimilar versions, according to a proposed antitrust class action lawsuit.

The lawsuit, filed on Monday, March 18, in Chicago federal court, accused AbbVie of using a so-called “patent thicket” to maintain a monopoly over the US$20-billion-a-year drug, which is used to treat arthritis and other diseases.

Full Content: Reuters

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.